Genmab — Februar 2011
-
og jeg tror med fordel vi skal have hevet vores regneark frem igen
-
hvis jeg var dem. Ville jeg guider arzerra på 100 mill
-
og så tage 4 opjusteringer i løbet af året
-
men de skal have modet til at guide. Ellers giver det ingen mening
-
hvis genmab guider 2011 med et underskud på 150-200 mill, så må nogen få øjenene op for den
-
jeg kan ikke se det nå så højt op
-
prøv at kig på regnearket det holder stadigt
-
med en halvering af milestones
-
arzerra værdi per aktie er ca. 78
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind